Merck & Co., Inc.: Late Breaking Data Released at American Diabetes Association Showed that the Investigational Use of JANUVIA(TM) (sitagliptin) and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in P

CHICAGO--(BUSINESS WIRE)--Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA™ (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.